U.S. Markets closed

Immutep Announces Upcoming Industry Conference Participation

SYDNEY, Australia, May 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces participation at upcoming industry conferences.

Conference: New York Academy of Sciences, Frontiers in Immunotherapy
   
Dates: May 14-15, 2019
   
Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York, USA
   
Participation: Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion titled “Novel Approaches from Biotech”
   
   
   
Conference: World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
   
Dates: May 15-17, 2019
   
Venue: Business Design Centre, London, UK
   
Presentation Title:    Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials
   
Presenter: Frédéric Triebel, CSO & CMO of Immutep
   
   
   
Conference: American Society for Clinical Oncology (ASCO) Annual Meeting
   
Dates: May 31 – June 4, 2019
   
Venue:  McCormick Place, Chicago, IL, USA
   

Abstract Number and Title: TPS2667, “A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).”

Poster Session: Developmental Immunotherapy and Tumor Immunobiology

Session Data and Time: Saturday, Jun 1, 8:00 - 11:00 a.m. CDT

Location: Hall A, Poster Board Number: #299b

Abstract Number and Title: TPS2651, “The “INSIGHT” Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities.”

Poster Session: Developmental Immunotherapy and Tumor Immunobiology

Session Data and Time: Saturday, Jun 1, 8:00 - 11:00 a.m. CDT

Location: Hall A, Poster Board Number: #291b

About Immutep

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Further information can be found on the Company’s website www.immutep.com or by contacting:

U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com

Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com

Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com